Summary Bryostatin I is a novel macrocyclic lactone activator of protein kinase C (PKC) which has clinical potential as an anti-cancer agent. The mechanism of action of this agent is unknown, but protein kinase C has been implicated. In order to investigate this possibility, we have developed P388 sublines resistant to bryostatin 1. by continuous challenge of the parent cell line with increasing incremental concentrations of the drug over 4 months. Cell lines were established at monthly intervals yielding four sublines: P388 BR A. which were removed at I month; P388'BR/B, obtained after 2 months; P388,BR C. obtained after 3 months; and P388 BR/D. which were established after 4 months. All four P388 BR sublines show an equal degree of resistance to the growth inhibitory effects of bryostatin 1. with a relative resistance ratio (RR) IC5, of approximately 4,000. The ability of the cytosol of cells to phosphorylate PKC-specific substrate is decreased by 41% for BR A. 57% for BR/B 80% for BR C and 94% for BR 'D compared with the parental cell line. even when grown in the absence of bryostatin 1 for up to 4 weeks. Similar decreases are seen for cytosolic phorbol ester binding and whole-cell PKC isoenzyme expression. All four P388 BR sublines show high and equal levels of cross-resistance to the PKC activatory phorbol ester, phorbol 12-myristate 13-acetate
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Bryostatin 1 is the prototype of a family of naturally occurring activators of protein kinase C (PKC) (Berkow & Kraft, 1985; Smith et al., 1985; Kraft et al., 1986; Fields et al., 1988) . It is a macrocyclic lactone (see Figure 1 ) isolated from the marine invertebrate Bugula neritina, a member of the phylum Ectoprocta (Pettit et al., 1982) . Bryostatin 1 exerts a wide range of biological effects, including antineoplastic activity. induction of differentiation, haemopoietic stimulation, platelet aggregation and immunoenhancing activity. Significant antineoplastic activity has been demonstrated against leukaemias, lymphomas, ovarian sarcoma, reticulum cell sarcoma and melanoma in a variety of murine and human cell lines and also in vivo against murine tumours-(NCI Antitumour Screening Program; Pettit et al., 1982; Dale & Gescher, 1989; Hornung et al., 1992 Bryostatin I shares many of its biological effects with phorbol esters, which are potent activators of PKC (Castagna et al.. 1982) . In several biological systems, however, bryostatin 1 behaves differently from phorbol esters. Unlike phorbol esters, bryostatin 1 does not induce differentiation in human bronchial epithelium (Jetten et al., 1989) or primary mouse epidermal cells (Sako et al., 1987) . Furthermore, bryosatin I and phorbol esters show differential effects on the hydrolysis of phosphatidylethanolamine (Kiss et al., 1991) . Furthermore. bryostatin 1 is inactive as a complete tumour promoter or carcinogen and acts to inhibit the tumourpromoting properties of phorbol esters (Hennings et al., 1987) . Some of these differences may be attributed to the diversity of responses to PKC activation mediated by the multiple isoforms that constitute the PKC family (a, , y, c, a, s.,., etc.) and their tissue-selective distribution (Nishizuka, 1988; Parker et al., 1989; Gescher, 1992) . Differences in the nature of the binding to the PKC receptor may provide an alternative mechanism for generating heterogeneity (Konig et al., 1985; Nakadate & Blumberg, 1987; Nelsestuen & Bazzi, 1991; Blumberg & Pettit, 1992) .
The substantial involvement of protein kinase C in cellular signal transduction gives it a central position in the regulation of growth and differentiation. It is, therefore, of great importance to identify and understand the mechanisms that account for the multiplicity of response within the protein kinase C pathway (Azzo et al., 1992) . In order to investigate the role of PKC in the anti-tumour effect of bryostatin 1, we have developed murine leukaemia sublines exhibiting resistance to the growth-inhibitory effects of the drug. These have been compared with the parental line in terms of their PKC activities and isoenzyme expression in order to determine whether alterations in this signalling is associated with decreased response to this agent. (McGown et al., 1983) . Both cell lines were grown as a suspension culture in RPMI medium supplemented with 10% horse serum. P388 PR8/22 was routinely maintained in the presence of DnR (0.1 g ml-') except during experimental procedures. All cell lines were mycoplasma free and replaced from frozen stock at 3 month intervals.
All cell lines were grown in the absence of bryostatin 1 for 4 weeks before experimentation.
Cell size was measured using a Coulter Channelizer 256.
Establishment P388 sublines resistant to bryostatin 1-induced growth inhibition We established P388 sublines resistant to bryostatin 1-induced growth inhibition by continuous exposure to increasing concentrations of the drug in vitro for over 4 months. Briefly, exponentially growing P388 cells were collected and adjusted to I03cells ml-'. Ten millilitres of this cell suspension was plated in 50 cm2 flasks and incubated for 7 days at 37C in a humidified atmosphere containing 5% carbon dioxide. Bryostatin I was dissolved in 100% ethanol and added at a final concentration of 0.5% ethanol to the cell suspension each week after the cells had been readjusted to IO3cellsml-' in fresh medium. The cell suspension was initially maintained in bryostatin 1 at a concentration of 0.5 nM and by gradual weekly increments was increased over 4 months to 1,000 nM. Cells were removed from bryostatin I challenge at monthly intervals (P388/BR/A, removed at 1 month and up to 50 nM bryostatin 1 challenge; P388/BR/B, 2 months and 100 nM; P388/BR/C, 3 months and 500 nM; and P388/BR/D, 4 months and 1,000 nM), adjusted to 106cells ml-' and frozen in triplicate at -270'C. On removal from the freezer, P388/BR/B, C and D were cultured in bryostatin 1-free medium for at least 4 weeks before each experiment. 
Growth inhibition studies

Results
Cell growth P388 cells were exposed to bryostatin I for up to 4 months. Bryostatin I was removed from the medium after 1, 2, 3 or 4 months and the cell lines obtained were designated P388/BR/ A. B, C and D respectively. After removal of the drug the cells grew at the same rate as the parental cell line. Significant differences were not observed in either cell size or protein content between the parent cell line and the sublines which had been exposed to bryostatin 1. The general characteristics of the parent line (P388) and cell lines P388/BR,A, P388/BR/B, P388 BR/C and P388/BR/D are summarised in Table I. Grow th inhibition Growth-inhibitory effects were assessed using a 5 day continuous exposure assay. The growth of P388/BR/A, B, C, and D cells was not inhibited when they were cultured with 100 nM bryostatin 1, however growth inhibition was seen at 500 nM. At I JiM proliferation of all lines was arrested by 52.6% in the case of P388/BR/A cells, 65.1 % for P388/BRz B, 59.9% for P388 BR/C cells and 48.1% for P388/BR1D (see of DnR for P388 (6 nM) was very similar to that seen in the bryostatin 1-resistant cell lines P388BR/A (9.5 nM), P388/BR/ B (10.2 nM), P388/BR/C (9.8 nM) and P388/BR/D (10.5 nM) (Figure 4) . The IC50 of bryostatin 1 for P388 (0.25 nM) was almost the same as that in the daunorubicin-resistant cell line, P388 PR8/22 (0.30 nM) ( Figure 5 ).
Whole-cell PKC activity Whole-cell PKC activity was measured in the parent cell line. DnR-resistant subline and bryostatin 1-resistant sublines (Figure 6 ). Whole-cell PKC activity in response to PMA was reduced to 59 ± 5% for P388 BRA, 43 ± 3% for BR/B, 20± 6% for BR/C and 6± 2% for BR/D compared with P388 cells (= 100%). Enzyme activity was not significantly altered in the daunorubicin-resistant cell line. P388 PR8'22 (110% ± 10%). PKC activity: P388BR A (13.90o + 1.470o of P388 control). P388BR B (34.5 + 1.550o). P388 BR C (15.2 + 1.60o) and P388 BR D )10.> |2.80o) compared to P388 controls 1000 o) (Fizure . C'-tosolic phorbol ester receptor levels are essentialiv unchangzed in the daunorubicin-resistant subline. P388 PPR8 22 97.8 5.3o00). Indeed. no PKC-x u-as detected in the BR D line bv this method. These results mirror closel1 the chanzes seen in whole-cell PKC phosphorylating activitv and cvtosolic PKC receptors. PKC-c levels in P388 PR8 22 wvere similar to those found in P388 w-ild-type cells.
Discussion
In common with phorbol esters. br-ostatin 1 is a very potent actixator of PKC. Br-ostatin 1 induces only a subset of the characteristic biological responses seen for phorbol esters. (Parker et al., 1989) and therefore the inhibitor is probably not recognised by these enzymes. Similarly. the affinity of the substrate is isoform dependent (Yasuda et al.. 1990 ). Therefore, although PKC activitv was reduced in these cells, it is not possible from the data to draw conclusions as to specific PKC isoforms. An analysis of these isoenzymes was necessary to address this issue. The expression of five individual PKC isoenzymes (cx. P. P. y and e) was examined. Only cx was detectable in the parental cell line. P388 (Figure 8) -P, -y or -c is important in mediating bryostatin 1 resistance and that down-regulation of PKC is either just part of the resistance mechanism or perhaps only an associated finding.
It is not known whether the decreased PKC activity arose from increased protein turnover or decreased protein production.
It is of interest that the P388 BR D subline. with 94% loss of whole-cell PKC activity, continued to grow at the same rate in serum supplemented with medium as the parent cell line. It seems. therefore, that only 6% of the PKC activity as measured by these techniques need be associated with normal rates of cell proliferation.
An increased activity of PKC has been reported in certain multidrug-resistant (MDR) cell lines (Palayoor et al.. 1987 ).
We observed a small increase in whole-cell PKC activity when the daunorubicin-resistant cell line. P388 PR8 22, was compared with the parent cell line. P388. However this increase was not significant.
We could not demonstrate any significant degree of crossresistance towards daunorubicin in the brvostatin 1-resistant cell lines. Equally. bryostatin 1 demonstrates similar growthinhibitorv effects on both P388 and the daunorubicin-resistant subline. We conclude that brvostatin 1 is not one of the 'mdr' class of agents. This is in agreement with Hait and De Rosa (1991) . who have shown that a subclone of HL-60 human promyelocytic leukaemia with acquired resistance to phorbol esters showed no change in sensitivity to doxorubicin.
In conclusion, this work has shown that the relationship between levels of PKC activity and sensitivity towards bryostatin 1 or phorbol esters is a complex one. However, continuous exposure of cells to bryostatin 1 results in the rapid development of a stable cell line with decreased total PKC activity. The importance of this residual PKC activity to cell proliferation has yet to be determined.
